andecaliximab (GS-5745) / Gilead  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
andecaliximab (GS-5745) / Gilead
GAMMA-1, NCT02545504 / 2015-001526-42: Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Checkmark Efficacy analysis in gastric cancer (andecaliximab discontinued)
Nov 2018 - Nov 2018: Efficacy analysis in gastric cancer (andecaliximab discontinued)
Completed
3
432
Europe, US, RoW
Andecaliximab, GS-5745, Placebo, Leucovorin, LV, 5-fluorouracil, 5-FU, Oxaliplatin, OXA
Gilead Sciences
Gastric Adenocarcinoma
05/19
05/19
NCT02520284 / 2014-005217-24: Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

Terminated
2/3
165
Canada, US, Europe, RoW
Andecaliximab, GS-5745, Placebo
Gilead Sciences
Ulcerative Colitis
09/16
11/16

Download Options